Deep sequencing reveals double mutations in cis of MPL exon 10 in myeloproliferative neoplasms

Haematologica

Volumn 96, Issue 4, 2011, Pages 607-611

  Pietra, Daniela ^a   Brisci, Angela ^b   Rumi, Elisa ^a   Boggi, Sabrina ^a   Elena, Chiara ^a   Pietrelli, Alessandro ^c   Bordoni, Roberta ^c   Ferrari, Maurizio ^b,d,e   Passamonti, Francesco ^a   de Bellis, Gianluca ^c   Cremonesi, Laura ^b   Cazzola, Mario ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b SAN RAFFAELE HOSPITAL   (Italy)

^c CNR   (Italy)

^d VITA SALUTE SAN RAFFAELE UNIVERSITY   (Italy)

^e Diagnostica e Ricerca San Raffaele   (Italy)

Author keywords

Deep sequencing; MPL exon 10; Mutation; Myeloproliferative neoplasm

Indexed keywords

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIRECT SEQUENCING; EXON; FEMALE; GENE; GRANULOCYTE; HIGH RESOLUTION MELT ANALYSIS; HUMAN; HUMAN CELL; JAK2 GENE; MAJOR CLINICAL STUDY; MALE; MPL GENE; MUTATIONAL ANALYSIS; MYELOID METAPLASIA; POLYCYTHEMIA VERA; POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SOMATIC MUTATION; T LYMPHOCYTE; THROMBOCYTHEMIA;

ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; EXONS; FEMALE; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; JANUS KINASE 2; MALE; MIDDLE AGED; MUTATION; MYELOPROLIFERATIVE DISORDERS; RECEPTORS, THROMBOPOIETIN; SEQUENCE ANALYSIS, DNA;

EID: 79953890796     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2010.034793     Document Type: Article

References (24)

1. Vannucchi AM, Guglielmelli P, Tefferi A. Advances in understanding and management of myeloproliferative neoplasms. CA Cancer J Clin. 2009;59(3):171-191.
2. Pikman Y, Lee BH, Mercher T, McDowell E, Ebert BL, Gozo M, et al. MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia. PLoS Med. 2006;3(7):e270.
3. Pardanani AD, Levine RL, Lasho T, Pikman Y, Mesa RA, Wadleigh M, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood. 2006;108(10):3472-3476.
4. Guglielmelli P, Pancrazzi A, Bergamaschi G, Rosti V, Villani L, Antonioli E, et al. Anaemia characterises patients with myelofibrosis harbouring Mpl mutation. Br J Haematol. 2007;137(3):244-247.
5. Williams DM, Kim AH, Rogers O, Spivak JL, Moliterno AR. Phenotypic variations and new mutations in JAK2 V617F-nega-tive polycythemia vera, erythrocytosis, and idiopathic myelofibrosis. Exp Hematol. 2007;35(11):1641-1646.
6. Beer PA, Campbell PJ, Scott LM, Bench AJ, Erber WN, Bareford D, et al. MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood. 2008; 112(1):141-149.
7. Vannucchi AM, Antonioli E, Guglielmelli P, Pancrazzi A, Guerini V, Barosi G, et al. Characteristics and clinical correlates of MPL 515W>L/K mutation in essential thrombo-cythemia. Blood. 2008;112(3):844-847.
8. Chaligne R, Tonetti C, Besancenot R, Roy L, Marty C, Mossuz P, et al. New mutations of MPL in primitive myelofibrosis: only the MPL W515 mutations promote a G1/S-phase transition. Leukemia. 2008;22(8): 1557-1566.
9. Schnittger S, Bacher U, Haferlach C, Beelen D, Bojko P, Burkle D, et al. Characterization of 35 new cases with four different MPLW515 mutations and essential throm-bocytosis or primary myelofibrosis. Haematologica. 2009;94(1):141-144.
10. Boyd EM, Bench AJ, Goday-Fernandez A, Anand S, Vaghela KJ, Beer P, et al. Clinical utility of routine MPL exon 10 analysis in the diagnosis of essential thrombo-cythaemia and primary myelofibrosis. Br J Haematol. 2010;149(2):250-257.
11. Beer PA, Ortmann CA, Stegelmann F, Guglielmelli P, Reilly JT, Larsen TS, et al. Molecular mechanisms associated with leukemic transformation of MPL-mutant myeloproliferative neoplasms. Haematologica. 2010;95(12):2153-2156.
12. Ding J, Komatsu H, Wakita A, Kato-Uranishi M, Ito M, Satoh A, et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the c-MPL gene, which encodes for the receptor for thrombopoietin. Blood. 2004;103(11):4198-4200.
13. Teofili L, Giona F, Martini M, Cenci T, Guidi F, Torti L, et al. Markers of myelopro-liferative diseases in childhood poly-cythemia vera and essential thrombo-cythemia. J Clin Oncol. 2007;25(9):1048-1053.
14. Liu K, Martini M, Rocca B, Amos CI, Teofili L, Giona F, et al. Evidence for a founder effect of the MPL-S505N mutation in eight Italian pedigrees with hereditary thrombocythemia. Haematologica. 2009;94(10): 1368-1374.
15. El-Harith el-HA, Roesl C, Ballmaier M, Germeshausen M, Frye-Boukhriss H, von Neuhoff N, et al. Familial thrombocytosis caused by the novel germ-line mutation p.Pro106Leu in the MPL gene. Br J Haematol. 2009;144(2):185-194.
16. Teofili L, Giona F, Torti L, Cenci T, Ricerca BM, Rumi C, et al. Hereditary thrombocy-tosis caused by MPLSer505Asn is associated with a high thrombotic risk, splenomegaly and progression to bone marrow fibrosis. Haematologica. 2010;95 (1):65-70.
17. Moliterno AR, Williams DM, Gutierrez-Alamillo LI, Salvatori R, Ingersoll RG, Spivak JL. Mpl Baltimore: a thrombopoietin receptor polymorphism associated with thrombocytosis. Proc Natl Acad Sci USA. 2004;101(31):11444-11447.
18. Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon:IARC, 2008.
19. Mesa RA, Verstovsek S, Cervantes F, Barosi G, Reilly JT, Dupriez B, et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): Consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res. 2007;31(6):737-740.
20. Malcovati L, Della Porta MG, Pietra D, Boveri E, Pellagatti A, Galli A, et al. Molecular and clinical features of refractory anemia with ringed sideroblasts associated with marked thrombocytosis. Blood. 2009;114(17):3538-3545.
21. Passamonti F, Rumi E, Pietra D, Della Porta MG, Boveri E, Pascutto C, et al. Relation between JAK2 (V617F) mutation status, granulocyte activation, and constitutive mobilization of CD34+ cells into peripheral blood in myeloproliferative disorders. Blood. 2006;107(9):3676-3682.
22. Oh ST, Simonds E F, Jones C, Hale MB, Goltsev Y, Gibbs KD Jr, et al. Novel mutations in the inhibitory adaptor protein LNK drive JAK-STAT signaling in patients with myeloproliferative neoplasms. Blood. 2010; 116(6):988-992.
23. Jones AV, Campbell PJ, Beer PA, Schnittger S, Vannucchi AM, Zoi K, et al. The JAK2 46/1 haplotype predisposes to MPL-mutat-ed myeloproliferative neoplasms. Blood. 2010;115(22):4517-4523.
24. Cleyrat C, Jelinek J, Girodon F, Boissinot M, Ponge T, Harousseau JL, et al. JAK2 mutation and disease phenotype: a double L611V/V617F in cis mutation of JAK2 is associated with isolated erythrocytosis and increased activation of AKT and ERK1/2 rather than STAT5. Leukemia. 2010;24(5): 1069-1073.